SGLT2 Inhibitors: A New Emerging Therapeutic Class in the Treatment of Type 2 Diabetes Mellitus
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
The incidence of type 2 diabetes mellitus is increasing worldwide. The existing therapeutic classes of antidiabetic drugs are not adequately effective in maintaining long‐term glycemic control in most patients, even when used in combination. One emerging novel therapeutic class of antidiabetic drugs is sodium glucose cotransporter 2 (SGLT2) inhibitors. SGLT2 accounts for 90% of the glucose reabsorption in the kidney. The SGLT2 inhibitors increase urinary excretion of glucose and lower plasma glucose levels in an insulin‐independent manner. Dapagliflozin, the most prominent molecule in this class, is currently in a phase III clinical trial. Other members of this class (eg, sergliflozin, remogliflozin) are also in different phases of clinical trials. This class of novel agents can effectively control blood sugar level without producing weight gain or hypoglycemia. Results of ongoing phase III clinical trials are crucial to determine whether the risk‐benefit ratio will allow approval of this new class of drugs for the management of type 2 diabetes mellitus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
List, J. F., Woo, V., Morales, E., Tang, W., & Fiedorek, F. T. (2009) · Diabetes Care · doi:10.2337/dc08-1863 · Cited by 698 · cited 1×
“The most frequently reported adverse events in phase II and III trials include constipation, diarrhea, nausea, urinary frequency, and genitourinary infections involving urinary tract infections (UTIs) and vulvovaginal infections.(27) In a recently reported phase III clinical trial, UTIs and genital infections were mor…”
Background
Cited by
Grempler, R., Thomas, L., Eckhardt, M., Himmelsbach, F., Sauer, A., Sharp, D. E., Bakker, R. A., Mark, M., Klein, T., & Eickelmann, P. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01517.x · Cited by 608
Cherney, D. Z., Perkins, B. A., Soleymanlou, N., Har, R., Fagan, N., Johansen, O., Woerle, H.-J., von Eynatten, M., & Broedl, U. C. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-28 · Cited by 470
SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects
Ferrannini, E., & Solini, A. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.243 · Cited by 458
Panchapakesan, U., Pegg, K., Gross, S., Komala, M. G., Mudaliar, H., Forbes, J., Pollock, C., & Mather, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054442 · Cited by 277
Aminoglycoside-Induced Cochleotoxicity: A Review
Jiang, M., Karasawa, T., & Steyger, P. S. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00308 · Cited by 261
Metadata
- Authors
- Ghosh, R. K., Ghosh, S. M., Chawla, S., & Jasdanwala, S. A.
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2012-04
- Volume
- 52
- Issue
- 4
- Pages
- 457-463
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- 1552-4604
- OpenAlex
- W1996143753
- Cited by
- 86
- References
- 1
- FWCI
- 7.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: SGLT2 Inhibitors: A New Emerging Therapeutic Class in the Treatment of Type 2 Diabetes Mellitus. https://app.cochat.ai/papers/10.1177/0091270011400604
- The paper
- Ghosh, R. K., Ghosh, S. M., Chawla, S., & Jasdanwala, S. A. (2012). SGLT2 Inhibitors: A New Emerging Therapeutic Class in the Treatment of Type 2 Diabetes Mellitus. The Journal of Clinical Pharmacology. https://doi.org/10.1177/0091270011400604
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.